The role of CD4+CD25+ regulatory T cells in Leishmania infection

Expert Opinion on Biological Therapy

Volumn 3, Issue 6, 2003, Pages 875-885

  Belkaid, Yasmine ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

CD4+CD25+ T cells; Leishmania; Memory; Parasite

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

CELL FUNCTION; CELL SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEISHMANIA; LEISHMANIA MAJOR; LEISHMANIASIS; MEMORY CELL; NONHUMAN; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS, CD4; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC MEMORY; LEISHMANIA MAJOR; LEISHMANIASIS; MICE; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

ANIMALIA; LEISHMANIA MAJOR; MURINAE; PROTOZOA;

EID: 0041334172     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.6.875     Document Type: Review

References (98)

1. SHEVACH EM: CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. (2002) 2(6):389-400.
2. SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. (1995) 155(3):1151-1164. This work is the first demonstration of the endogenous status and role of CD4+CD25+ T cells.
3. SAKAGUCHI S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell (2000) 101(5):455-458.
4. KINGSLEY CI, KARIM M, BUSHELL AR, WOOD KJ: CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. (2002) 168(3):1080-1086.
5. IWASHIRO M, MESSER RJ, PETERSON KE et al.: Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection. Proc. Natl. Acad. Sci. USA (2001) 98(16):9226-9230.
6. HORI S, CARVALHO TL, DEMENGEOT J: CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur. J. Immunol. (2002) 32(5):1282-1291.
7. ITOH M, TAKAHASHI T, SAKAGUCHI N et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. (1999) 162(9):5317-5326.
8. SAKAGUCHI S, SAKAGUCHI N, SHIMIZU J et al.: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Arv. (2001) 182:18-32.
9. MCHUGH RS, WHITTERS MJ, PICCIRILLO CA et al.: CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. [comment]. Immunity. (2002) 16(2):311-323.
10. SHIMIZU J,YAMAZAKI S, TAKAHASHI T, ISHIDA Y, SAKAGUCHI S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. [comment]. Nat. Immun. (2002) 3(2):135-142.
11. HORI S, NOMURA T, SAKAGUCHI S: Control of regulatory T cell development by the transcription factor Foxp3. [comment]. Science (2003) 299(5609):1057-1061. References [11-13] were the first to show that Foxp3 is a specific marker for CD4+CD25+ regulatory T cells.
12. FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. [comment]. Nat. Immun. (2003) 4 (4):330-336. See [11]
13. KHATTRI R, COX T, YASAYKO SA, RAMSDELL F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. [comment]. Nat. Immun. (2003) 4(4):337-342. See [11].
14. THORNTON AM, SHEVACH EM: CD4+CD25+ immunoregulatory T cells suppress polydonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. (1998) 188(2):287-296. A role for CTLA-4 and surface-expressed TGF-β in such inhibition has been suggested, but remains controversial.
15. NAKAMURA K, KITANI A, STROBER W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. (2001) 194(5):629-644.
16. PICCIRILLO CA, LETTERIO JJ, THORNTON AM et al.: CD4+CD25+ regulatory T cells can mediate suppressor function in the absence of transforming growth factor {beta} 1 production and responsiveness. J Exp. Med (2002) 196(2):237-246.
17. TAKAHASHI T, TAGAMI T, YAMAZAKI S et al.: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med (2000) 192(2):303-310.
18. PICCIRILLO CA, SHEVACH EM: Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J. Immunol. (2001) 167(3):1137-1140.
19. TAKAHASHI T, KUNIYASU Y, TODA M et al.: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. (1998) 10(12):1969-1980.
20. PASARE C, MEDZHITOV R: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. [comment]. Science (2003) 299(5609):1033-1036. This work demonstrates that regulatory T cells can themselves be controlled by the level of activation of dendritic cells.
21. READ S, MALMSTROM V, POWRIE F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. (2000) 192(2):295-302.
22. MALOY KJ, SALAUN L, CAHILL R, DOUGAN G, SAUNDERS NJ, POWRIE F: CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med. (2003) 197:111-119.
23. MCGUIRK P, MCCANN C, MILLS KH: Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper Type 1 responses by Bordetella pertussis. J. Exp. Med. (2002) 195(2):221-231.
24. JONULEIT H, SCHMITT E, KAKIRMAN H et al.: Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J. Exp. Med (2002) 196(2):255-260.
25. DIECKMANN D, BRUETT CH, PLOETTNER H, LUTZ MB, SCHULER G: Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. [erratum appears in J. Exp. Med. (2002) 196(4):559]. J. Exp. Med. (2002) 196(2):247-253.
26. SACKS DL: Leishmania-sand fly interactions controlling species-specific vector competence. Cell Microbiol. (2001) 3(4):189-196.
27. BOGDAN C, DONHAUSER N, DORING R et al.: Fibroblasts as host cells in latent leishmaniosis. J. Exp. Med. (2000) 191(12):2121-2130. The first analysis of host cells in a latendy infected site.
28. MOLL H, FLOHE S, BLANK C: Dendritic cells seclude Leishmania parasites that persist in cured mice- -a role in the maintenance of T-cell memory? Adv. Exp. Med. Biol. (1995) 378:507-509.
29. KHARAZMI A, KEMP K, ISMAIL A et al.: T-cell response in human leishmaniasis. Immunol. Lett. (1999) 65(1-2):105-108.
30. MOSSALAYI MD, AROCK M, MAZIER D, VINCENDEAU P, VOULDOUKIS I: The human immune response during cutaneous leishmaniasis: NO problem. Parasitology Today (1999) 15(8):342-345.
31. SACKS D, NOBEN-TRAUTH N: The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. (2002) 2 (11):845-858.
32. BOGDAN C, ROLLINGHOFF M, DIEFENBACH A. The role of nitric oxide in innate immunity. Immunol. Rev. (2000) 173:17-26.
33. VARDY DA, COHEN A, KACHKO L, ZVULUNOV A, FRANKENBURG S: Relapse of cutaneous leishmaniasis in a patient with an infected subcutaneous rheumatoid nodule. Br. J. Dermatol. (1999) 141(5):914-917.
34. CHOI CM, LERNER EA: Leishmaniasis as an emerging infection. J. Invest. Dermatol. (2001) 6(3):175-182.
35. MILON G, BELKAID Y, MOUFQIA J et al.: Mononudear phagocytes and dendritic leukocytes in the skin. Clin. Dermatol. (1996) 14(5):465-470.
36. REINER SL, LOCKSLEY RM: The regulation of immunity to Leishmania major. Ann. Rev Immunol (1995) 13:151-177. References [36-47] established the mechanism of resistance to Leishmania infection.
37. SCOTT P, FARRELL JP: Experimental cutaneous leishmaniasis: induction and regulation of T cells following infection of mice with Leishmania major. Chem. Immunol. (1998) 70:60-80. See [36].
38. LIEW FY, HALE C, HOWARD JG: Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells. J. Immunol. (1982) 128(4):1917-1922. See [36].
39. TITUS RG, MILON G, MARCHAL G et al.: Involvement ofspecific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis. Eur. J. Immunol. (1987) 17(10):1429-1433. See [36].
40. BELOSEVIC M, FINBLOOM DS, VAN DER MEIDE PH, SLAYTER MV, NACY CA: Administration of monoclonal anti-IFN-gamma antibodies in viabrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. (1989) 143(1):266-274. See [36].
41. HEINZEL FP, RERKO RM, HATAM F, LOCKSLEY RM: IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J. Immunol. (1993) 150(9):3924-3931. See [36].
42. SYPEK JP, CHUNG CL, MAYOR SE et al.: Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper Type 1 immune response. J. Exp. Med. (1993) 177(6):1797-1802. See [36].
43. STENGER S, THURING H, ROLLINGHOFF M, BOGDAN C: Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J. Exp. Med. (1994) 180(3):783-793. See [36].
44. CHAKKALATH HR, THEODOS CM, MARKOWITZ JS et al.: Class II major histocompatibility complex-defident mice initially control an infection with Leishmania major but succumb to the disease. J. Infect. Dis. (1995) 171(5):1302-1308. See [36].
45. ERB K, BLANK C, RITTER U, BLUETHMANN H, MOLL H: Leishmania major infection in major histocompatibility complex class II-deficient mice: CD8+ T cells do not mediate a protective immune response. Immunobiology (1996) 195(2):243-260. See [36].
46. KAMANAKA M, YU P, YASUI T et al.: Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity (1996) 4(3):275-281. See [36] and [48].
47. CAMPBELL KA, OVENDALE PJ, KENNEDY MK et al.: CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity (1996) 4(3):283-289. See [36] and [48].
48. LANG T, COURRET N, COLLE JH, MILON G, ANTOINE JC: The levels and patterns of cytokines produced by CD4 T lymphocytes of BALB/c mice infected with Leishmania major by inoculation into the ear dermis depend on the infectiousness and size of the inoculum. Infect. Immun. (2003) 71(5):2674-2683. References [46-48] showed that early IL-4 production by LACK-reactive cells controls susceptibility to L. major.
49. MENON JN, BRETSCHER PA: Parasite dose determines the Th1/Th2 nature of the response to Leishmania major independently of infection route and strain of host or parasite. Eur. J. Immunol. (1998) 28(12):4020-4028.
50. JULIA V, RASSOULZADEGAN M, GLAICHENHAUS N: Resistance to Leishmania major induced by tolerance to a single antigen. Science (1996) 274(5286):421-423.
51. LAUNOIS P, MAILLARD I, PINGEL S et al.: IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity (1997) 6(5):541-549.
52. HIMMELRICH H, LAUNOIS P, MAILLARD I et al.: In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J. Immunol. (2000) 164(9):4819-4825.
53. JULIA V, GLAICHENHAUS N: CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant BIO.D2 mice. Infect. Immun. (1999) 67(7):3641-3644.
54. STETSON DB, MOHRS M, MALLET-DESIGNE V, TEYTON L, LOCKSLEY RM: Rapid expansion and IL-4 expression by Leishmania-specific naive helper T cells in vivo. Immunity (2002) 17(2):191-200.
55. CHATELAIN R, VARKILA K, COFFMAN RL: IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. (1992) 148(4):1182-1187.
56. HEINZEL FP, SCHOENHAUT DS, RERKO RM, ROSSER LE, GATELY MK: Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. (1993) 177(5):1505-1509.
57. HONDOWICZ BD, PARK AY, ELLOSO MM, SCOTT P: Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice. Eur. J. Immunol. (2000) 30(7):2007-2014.
58. GROUX H, COTTREZ F, ROULEAU M et al.: A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J. Immunol. (1999) 162(3):1723-1729.
59. YAMAKAMI K, AKAO S, TADAKUMA T et al.: Administration of plasmids expressing interleukin-4 and interleukin-10 causes BALB/c mice to induce a T helper 2-type response despite the expected T helper 1-type response with a low-dose infection of Leishmania major. Immunology (2002) 105(4):515-523.
60. KANE MM, MOSSER DM: The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol (2001) 166(2):1141-1147. This work demonstrates that IL-10 contributes to susceptibility to L. major in BALB/c mice.
61. NOBEN-TRAUTH N, LIRA R, NAGASE H, PAUL WE, SACKS DL: The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. (2003) 170(10):5152-5158.
62. REINER SL, ZHENG S, WANG ZE, STOWRING L, LOCKSLEY RM: Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J. Exp. Med. (1994) 179(2):447-456.
63. POWRIE F, CORREA-OLIVEIRA R, MAUZE S, COFFMAN RL: Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. (1994) 179(2):589-600. The first demonstration that regulatory T cells were involved in parasitic (L. major) infection.
64. ASEFFA A, GUMY A, LAUNOIS P et al.: The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells. J. Immunol. (2002) 169(6):3232-3241. Provides the first demonstration that a Th2 response can be controlled by CD4+CD25+T cells. See also [66].
65. XU D, LIU H, KOMAI-KOMA M et al.: CD4(+)CD25(+) Regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J. Immunol. (2003) 170:394-399. See [64] and [66].
66. MITCHELL GF, CURTIS JM, SCOLLAY RG, HANDMAN E: Resistance and abrogation of resistance to cutaneous leishmaniasis in reconstituted BALB/c nude mice. Aust. J. Exp. Biol Med. Sci. (1981) 59(Pt 5):539-554. References [64-66] demonstrate that during latency, parasite replication is under immune pressure.
67. ERNST B, LEE DS, CHANG JM, SPRENT J, SURH CD: The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity (1999) 11(2):173-181.
68. WARBURG A, SCHLEIN Y: The effect of post-bloodmeal nutrition of Phlebotomus papatasi on the transmission of Leishmania major. Am. J. Trop. Med. Hyg. (1986) 35(5):926-930.
69. BELKAID Y, MENDEZ S, LIRA R et al.: A natural model of Leishmania major infection reveals a prolonged 'silent' phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. (2000) 165(2):969-977. The first description of the low-dose intradermal model of L. major infection.
70. NICOLAS L, SIDJANSKI S, COLLE JH, MILON G: Leishmania major reaches distant cutaneous sites where it persists transiently while persisting durably in the primary dermal site and its draining lymph node: a study with laboratory mice. Infect. Immun. (2000) 68(12):6561-6566.
71. VON STEBUT E, BELKAID Y, JAKOB T, SACKS DL, UDEY MC: Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J. Exp Med. (1998) 188(8):1547-1552. This reference provides the first demonstration that L major activates dendritic cells.
72. MOLL H, FLOHE S, ROLLINGHOFF M: Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response. Eur. J. Immunol. (1995) 25(3):693-699.
73. BELKAID Y, HOFFMANN KF, MENDEZ S et al.: The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. (2001) 194(10):1497-1506. The demonstration that IL-10 is required for L. major latency.
74. MULLER I, GARCIA-SANZ JA, TITUS R, BEHIN R, LOUIS J: Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major. Immunol Rev. (1989) 112:95-113.
75. STENGER S, DONHAUSER N, THURING H, ROLLINGHOFF M, BOGDAN C: Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. (1996) 183(4):1501-1514.
76. STOBIE L, GURUNATHAN S, PRUSSIN C et al.: The role of antigen and IL-12 in sustaining Thl memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad Sci. USA (2000) 97(15):8427-8432.
77. AEBISCHER T, MOODY SF, HANDMAN E: Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immun. (1993) 61(1):220-226. This paper provides the first demonstration that L. major can persist following clinical cure in a genetically resistant host.
78. MENDEZ S, GURUNATHAN S, KAMHAWI S et al.: The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. (2001) 166(8):5122-5128.
79. MULLER I, LOUIS JA: Immunity to experimental infection with Leishmania major, generation ofprotective L3T4+ T cell clones recognizing antigen(s) associated with live parasites. Eur. J. Immunol. (1989) 19(5):865-871.
80. BELKAID Y, PICCIRILLO AC, MENDEZ S, SHEVACH EM, SACKS DL: CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature (2002) 420:502-507. This reference provides the first demonstration that CD4+CD25+ T cells are necessary for parasite latency.
81. GAZZINELLI RT, OSWALD IP, JAMES SL, SHER A: IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J. Immunol. (1992) 148(6):1792-1796. This work demonstrates that IL- 10 exposure renders macrophages incapable of killing pathogen.
82. MOORE KW, DE WAAL MALEFYT R, COFFMAN RL, O'GARRA A: Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol. (2001) 19:683-765.
83. CARRERA L, GAZZINELLI RT, BADOLATO R et al.: Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J. Exp. Med. (1996) 183 (2):515-526. This reference describes, for the first time, the selective inhibition of IL-12 on Leishmania sp. infected macrophages.
84. BELKAID Y, KAMHAWI S, MODI G et al.: Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. (1998) 188(10):1941-1953.
85. UZONNA JE, WEI G, YURKOWSKI D, BRETSCHER P: Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. (2001) 167(12):6967-6974. This work provides the first demonstration that in a susceptible background, sterile cure is not compatible with maintenance of memory.
86. HAUSMANN S, WUCHERPFENNIG KW: Activation of autoreactive T cells by peptides from human pathogens. Curr. Opin. Immunol. (1997) 9(6):831-838.
87. DE OLIVEIRA MR, TAFURI WL, NICOLI JR et al.: Influence of microbiota in experimental cutaneous leishmaniasis in Swiss mice. Rev. Int. Med. Trop. Sao Paula (1999) 41(2):87-94. This work demonstrates that the presence of gut flora influences the susceptibility to Leishmania infection.
88. JULIA V, MCSORLEY SS, MALHERBE L et al.: Priming by microbial antigens from the intestinal flora determines the ability of CD4+ T cells to rapidly secrete IL-4 in BALB/c mice infected with Leishmania major. J. Immunol. (2000) 165(10):5637-5645.
89. MILON G, TITUS RG, CEROTTINI JC, MARCHAL G, LOUIS JA: Higher frequency of Leishmania major-specific L3T4+ T cells in susceptible BALB/c as compared with resistant CBA mice. J. Immunol. (1986) 136(4):1467-1471.
90. BOURREAU E, COLLET M, PREVOT G et al.: IFN-gamma-producing CD45RA+CD8+ and IL-10-producing CD45RA-CD4+ T cells generated in response to LACK in naive subjects never exposed to Leishmania. Eur. J. Immunol. (2002) 32(2):510-520.
91. CARAMALHO I, LOPES-CARVALHO T, OSTLER D et al.: Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. [comment]. J. Exp. Med (2003) 197(4):403-411. This reference demonstrates that CD4+CD25+ T cell function can be regulated through TLR.
92. KARP CL, EL-SAFI SH, WYNN TA et al.: In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest. (1993) 91(4):1644-1648.
93. MURRAY HW, LU CM, MAUZE S et al.: Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. (2002) 70(11):6284-6293.
94. BARRAL-NETTO M, BARRAL A, BROWNELL CE et al.: Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science (1992) 257(5069):545-548.
95. BARRAL A, TEIXEIRA M, REIS P et al.: Transforming growth factor-beta in human cutaneous leishmaniasis. Am. J. Pathol. (1995) 147(4):947-954.
96. WILSON ME, YOUNG BM, DAVIDSON BL, MENTE KA, MCGOWAN SE: The importance of TGF-beta in murine visceral leishmaniasis. J. Immunol. (1998) 161(11):6148-6155.
97. LI J, HUNTER CA, FARRELL JP: Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J. Immunol. (1999) 162(2):974-979.
98. GOMES NA, GATTASS CR BARRETO-DE-SOUZA V, WILSON ME, DOSREIS GA: TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J. Immunol. (2000) 164(4):2001-2008.